CI

At a glance

ClinicalIndex Comparison Record
Phase 3Withdrawn· 0 enrolled
Drug / intervention
Sildenafil 50 mg Oral Tablet +1 moredrug
Likely dose
Sildenafil 50 mg Oral Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06377098
NCT06377098Phase 3Withdrawn
Withdrawn

Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-Resource Settings: A Randomized Pilot Feasibility Trial: Pilot Randomized Intrapartum Sildenafil in Mothers

University of Alabama at Birmingham·interventional·Posted Apr 22, 2024·Updated Sep 16, 2025

In Brief

A Phase 3 clinical trial evaluating Sildenafil 50 mg Oral Tablet and Placebo Oral Tablet for Neonatal Asphyxia and 3 related conditions. Withdrawn before enrollment, across 3 sites in 3 countries.

Signals

Trial was withdrawn before enrollment

Detailed Summary

The goal of this feasibility pilot clinical trial is to learn if sildenafil citrate 50mg orally, up to three times during labor, can be appropriately administered, with limited clinical side effects, to laboring mothers to determine feasibility across a spectrum of available healthcare resources. The main questions it aims to answer are: * What are the fetal heart rate monitoring practices in a low-resource setting? * What are the indications for operative delivery in a low-resource? * What is the rate of relevant primary and secondary outcomes to possibly target in a large RCT of intrapartum sildenafil? * What is the limited effect size of sildenafil citrate on maternal and neonatal outcomes in a low-resource setting? Researchers will compare the administration of sildenafil citrate 50 mg orally to a placebo (a look-alike substance that contains no drug) to see if procedures are feasible, the drug is tolerated, the target outcomes are achievable, and effect size is as expected. Participants will: * Take Sildenafil 50 mg/placebo every eight hours or a placebo every eight hours for up to 24 hours during labor * Have the (mothers \& babies) medical charts reviewed for outcomes, including fetal distress, operative delivery, maternal side effects, neonatal bag \& mask ventilation, Apgar scores, and seizures. * Have a neonatal neurological assessment prior to discharge * Have phone call assessments for re-hospitalization or mortality 7 days post-delivery * Receive child development assessments at 1 year, 2 years and 3 years of age by the Ages and Stages Questionnaire administered via a telephone call The results of this feasibility pilot trial will be used to inform the design and conduct of a large pragmatic randomized controlled trial to determine if sildenafil citrate, compared to placebo, will decrease fetal distress and perinatal asphyxia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCameroon, Kenya, Zambia

Timeline

Phase 3WithdrawnFinished
2025202620272028
First PostedApr 22, 2024
Enrollment StartMay 1, 2025
Primary CompletionAug 31, 2026
Study CompletionSep 30, 2028
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 2.2 years ago

Interventions

Sildenafil 50 mg Oral Tabletdrug

Sildenafil 50 mg given orally every eight hours up to three times while mother is in labor

Placebo Oral Tabletdrug

Placebo table given orally every eight hours up to three times while mother is in labor